AEterna Zentaris brings on David Dodd as new CEO

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here each Friday.

AEterna Zentaris brings on new CEO

Canada's AEterna Zentaris ($AEZS), a developer of oncology and endocrine therapies, has hired David Dodd to the company's top position. Dodd has been involved in the sale of Stem Cell Sciences and Serologicals Corporation and is currently the CEO of RiversEdge BioVentures, which he founded. The new appointment represents AEterna's shift of focus from R&D to commercialization of what it calls "promising" compounds in its pipeline. Release

AEterna Zentaris
David A. Dodd became the new CEO of AEterna Zentaris.

Aushon BioSystems
Susan Vogt was named CEO of Aushon BioSystems.

Medical Devices

Aushon BioSystems has named Susan Vogt as CEO. Most recently, Vogt led the turnaround of diagnostics reagents company SeraCare Life Sciences as president and CEO. Story | Release

Biotech

Vanda Pharmaceuticals Inc. ($VNDA) has named Dr. Paolo Baroldi as its senior vice president and chief medical officer. Baroldi has been the acting chief medical office since October 2012. Before joining Vanda in 2009, he served in senior clinical development positions at Galileo Research, Supernus Pharmaceuticals, Chiesi Farmaceutici SpA, and Novartis ($NVS). Release

> Kleanthis G. Xanthopoulos joined the Board of Directors at Zosano Pharma. Xanthopoulos is currently the president and CEO of Regulus Therapeutics ($RGLS). Release

Immunotech Laboratories brought on Blaine Nabors as the company's vice president of business development. Release

Stella M. Sung joined Tauriga Sciences as the company's chief operating officer. Sung comes from Avita Medical, where she was the business development officer. Release

Ambit Biosciences appointed David Parkinson to its board of directors. Parkinson is a venture partner at New Enterprise Associates. Release

AtheroNova brought on John Kastelein as a member of the medical advisory board. Kastelain is chairman of the department of vascular medicine and strategic chair of genetics in cardiovascular disease at the Academic Medical Center of the University of Amsterdam. Release

Covagen named Elias Papatheodorou the company's new chief business officer. Papatheodorou was senior vice president of business development and operations at MediGene before coming to Covagen. Release

Pharma

Matthew Stober has been named senior vice president of operations at Hospira ($HSP). Before joining Hospira in 2011 as its corporate vice president of U.S. Pharma Operations, Stober worked at Johnson & Johnson ($JNJ), where he served as the vice president and global platform leader for solids, parenterals and vaccines. Release

Astellas Pharma made Songlin Xue the company's head of Global Pharmacovigilance. Xue was most recently the senior vice president of the same department at Takeda Pharmaceutical. Release

Drug Delivery

Joshua Hexter was appointed chief operating officer and vice president of business development at Oramed Pharmaceuticals ($ORMP). Previously, Hexter was executive director of corporate in-licensing at BioLineRx ($BLRX). Release

Research

Microsoft's ($MSFT) Craig Mundie is among three new board members to join the Institute for Systems Biology. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.